Evaxion to Unveil Potentially Groundbreaking AI-Immunology™ Precision Cancer Vaccine Concept
29 November 2023 - 12:27AM
Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a
clinical-stage TechBio company specializing in developing
AI-Immunology™ powered vaccines, proudly announces the presentation
of its novel precision vaccine concept at the 65th American Society
of Hematology (ASH) Annual Meeting, taking place in San Diego,
California, from December 9-12, 2023.
Selected for an Oral
Presentation – Evaxion has been chosen
for an oral presentation from a competitive pool of >5000
submitted abstracts. The presentation will unveil a breakthrough
achievement using the Company’s proprietary AI target discovery and
development platform, AI-Immunology™. Based upon a novel source of
targets, endogenous retroviruses (ERVs), combined with unique data
insights, Evaxion has discovered a novel concept for precision
vaccines in hematological malignancies and selected solid
cancers.
Tailored Precision Vaccines
– The precision vaccines are tailored to the
specific tumor profiles and immune systems of patient groups. This
marks a significant stride forward in addressing the complexities
of cancers, including hematological malignancies. The discovery
will potentially allow for a broader than previously expected
application of vaccines in cancer therapy.
Event Details:
Title: |
“Endogenous
Retroviral Elements Constitute a Promising Vaccine Antigen Source
for Hematological Malignancies” |
Talk: |
243 |
Session: |
Emerging Tools, Techniques and Artificial Intelligence in
Hematology: Emerging Technologies for Understanding Benign and
Malignant Hematology |
Session: |
803 |
Location: |
Room 30 – San Diego Convention Center |
Time: |
Saturday, December 9, 2:30 p.m. PDT |
Presenter: |
Anders Bundgård Sørensen, Project Director of Research and
Discovery |
|
|
About ERVsEndogenous
retroviruses (ERVs) are remnants of ancient viruses incorporated
into the human genome. While dormant in normal cells due to strict
epigenetic control, cancer cells may express these traces, making
ERVs ideal targets for cancer vaccines.
About EVAXIONEvaxion Biotech
A/S is a pioneering TechBio company based upon its AI platform,
AI-Immunology™. Evaxion’s proprietary and scalable AI prediction
models harness the power of artificial intelligence to decode the
human immune system and develop novel immunotherapies for cancer,
bacterial diseases, and viral infections. Based upon
AI-Immunology™, Evaxion has developed a clinical-stage oncology
pipeline of novel personalized vaccines and a preclinical
infectious disease pipeline in bacterial and viral diseases with
high unmet medical needs. Evaxion is committed to transforming
patients’ lives by providing innovative and targeted treatment
options. For more information about Evaxion and its groundbreaking
AI-Immunology™ platform and vaccine pipeline, please visit our
website.
Forward-Looking
Statement This announcement contains
forward-looking statements within the meaning of Section 27A
of the Securities Act of 1933, as amended, and Section 21E of the
Securities Exchange Act of 1934, as amended. The
words “target,” “believe,” “expect,” “hope,” “aim,” “intend,”
“may,” “might,” “anticipate,” “contemplate,” “continue,”
“estimate,” “plan,” “potential,” “predict,” “project,” “will,” “can
have,” “likely,” “should,” “would,” “could,” and other words and
terms of similar meaning identify forward-looking
statements. Actual results may differ materially from those
indicated by such forward-looking statements as a result of various
factors, including, but not limited to, risks related to: our
financial condition and need for additional capital; our
development work; cost and success of our product development
activities and preclinical and clinical trials; commercializing any
approved pharmaceutical product developed using our AI platform
technology, including the rate and degree of market acceptance of
our product candidates; our dependence on third parties including
for conduct of clinical testing and product manufacture; our
inability to enter into partnerships; government regulation;
protection of our intellectual property rights; employee matters
and managing growth; our ADSs and ordinary shares, the impact
of international economic, political, legal, compliance, social and
business factors, including inflation, and the effects on
our business from the worldwide ongoing COVID-19 pandemic and
the ongoing conflict in the region
surrounding Ukraine and Russia and the Middle
East; and other uncertainties affecting our business
operations and financial condition. For a further discussion
of these risks, please refer to the risk factors included in our
most recent Annual Report on Form 20-F and other
filings with the U.S. Securities and Exchange Commission
(SEC), which are available
at www.sec.gov. We do not assume any
obligation to update any forward-looking statements except as
required by law.
Contact Information
Evaxion Biotech A/S
Christian Kanstrup
Chief Executive Officer
cka@evaxion-biotech.com
Source: Evaxion Biotech
Evaxion Biotech AS (NASDAQ:EVAX)
Historical Stock Chart
From Apr 2024 to May 2024
Evaxion Biotech AS (NASDAQ:EVAX)
Historical Stock Chart
From May 2023 to May 2024